Auranofin, Hydroxychloroquine, Methotrexate, and Prednisone Combination Therapy

The combination of auranofin, hydroxychloroquine, methotrexate, and prednisone is used as a therapeutic approach for rheumatoid arthritis (RA), particularly for patients with aggressive or "at-risk" synovitis. This combination therapy represents an alternative to the traditional therapeutic pyramid approach, which involved sequential single-drug treatment that was often considered too little, too late, and ineffective in preventing disease progression or joint damage[10]. ## Efficacy and Clinical Use This specific four-drug combination is part of a broader approach to RA treatment that aims to achieve early control of inflammation and then "bridge down" to a simplified maintenance program. The combination therapy approach has shown several benefits: - More effective control of inflammation compared to single-drug therapy[2][10] - Higher rates of remission (37% with combination therapy vs. 18% with single-drug therapy after 24 months)[2] - Clinical improvement of at least 50% achieved in 75% of combination therapy patients at one year compared with 60% of those on single-drug therapy[2] - Potentially fewer withdrawals due to lack of response compared to single-drug therapy[1] ## Individual Components and Mechanisms **Methotrexate (MTX):** - Considered the first-line DMARD (disease-modifying antirheumatic drug) for most RA patients[4] - Has a relatively rapid onset of action (6-8 weeks), good efficacy, favorable toxicity profile, and relatively low cost[4] - Anti-inflammatory effects appear related to interruption of adenosine and effects on other inflammatory pathways[4] **Hydroxychloroquine (HCQ):** - When combined with methotrexate, increases exposure to methotrexate, which may explain the increased potency of this combination[6] - Increases the area under the concentration-time curve (AUC) for MTX while decreasing the maximum MTX concentration (Cmax)[6] **Auranofin:** - Gold compound used as a DMARD - When used alone, shows a slower onset of response compared to methotrexate alone or in combination[1] **Prednisone:** - Adding prednisone to methotrexate has been shown to reduce disease activity and radiographic progression[9] - May decrease rates of common methotrexate side effects, including nausea[9] - Allows patients to stay on methotrexate longer and at higher doses[9] ## Safety Considerations - Combination therapy does not appear to be more hazardous than single-drug regimens[2] - Withdrawals due to adverse drug reactions may be slightly more common with combination therapy, but differences are often not statistically significant[1] - Extra vigilance for MTX adverse effects during combination therapy with HCQ is recommended, especially if renal function is decreased[6] - The reduced Cmax of MTX observed during coadministration with HCQ may explain diminution of acute liver adverse effects[6] This combination approach represents a shift from the traditional therapeutic pyramid to more aggressive early treatment for RA patients, particularly those with more severe disease presentations.